Eli Lilly Alzheimer’s drug setback extends rival Biogen’s lead – analysts – Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/XT33J4GYXNLZ5IZKT6BUSJKRZM.jpg "Eli Lilly Alzheimer’s drug setback extends rival Biogen’s lead – analysts – Reuters")
Jan 20 (Reuters) – The U.S. health regulator’s rejection of accelerated approval for Eli Lilly and Co’s Alzheimer’s disease drug extends the market lead for rivals Eisai and Biogen’s treatment by mon… [read more]
